--- title: "Epigenica AB launches EpiFinder™ cNUC: The first platform to simultaneously profile multiple histone marks and DNA methylation directly from circulating nucleosomes in plasma and serum" description: Epigenica has announced the launch of EpiFinder™ cNUC, offering researchers a new way to obtain scalable, high‑resolution epigenomic information from low‑volume liquid biopsy samples. image: https://news.lifesciencenewswire.com/hubfs/EpiFinderTM%20cNUC.png --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Epigenica AB launches EpiFinder™ cNUC: The first platform to simultaneously profile multiple histone marks and DNA methylation directly from circulating nucleosomes in plasma and serum](https://news.lifesciencenewswire.com/newsroom/epigenica-ab-launches-epifinder-cnuc-the-first-platform-to-simultaneously-profile-multiple-histone-marks-and-dna-methylation-directly-from-circulating-1771597224314b) February 25, 2026 [![EpiFinderTM cNUC](https://news.lifesciencenewswire.com/hs-fs/hubfs/EpiFinderTM%20cNUC.png?width=218&height=218&name=EpiFinderTM%20cNUC.png)](https://drive.google.com/file/d/11esCe16DKbK-qZIm4CYnhnul5aJqGQip/view?usp=sharing)Epigenica today announces the launch of EpiFinder™ cNUC, a truly unique product for liquid biopsies that significantly expands the capabilities of epigenomic research by delivering deep insights directly from circulating nucleosomes. As the first product capable of simultaneously profiling up to 5 histone post‑translational modifications together with DNA methylation across multiple samples, EpiFinder™ cNUC offers researchers an entirely new way to obtain scalable, high‑resolution epigenomic information from low‑volume liquid biopsy samples. With the ability to run up to 24 samples in a single workflow, EpiFinder™ cNUC reduces hands‑on time and technical variability while generating robust and quantitative data without the need for spike‑in controls. Its innovative chemistry enables the simultaneous analysis of up to six epigenetic marks from just 200 µL of sample, providing powerful insights in studies where sample availability is limited. The product profiles epigenetic marks directly from circulating nucleosomes, without requiring nucleosome extraction, preserving biological integrity, simplifying the workflow, and saving the cost of DNA purification. EpiFinder™ cNUC is complemented by an intuitive open‑source data analysis pipeline that requires no advanced bioinformatics expertise, enabling researchers to move seamlessly from data generation to biological interpretation. Its flexible design allows users to tailor sample throughput and selected epigenetic markers to match project objectives, from early exploratory studies to large‑scale biomarker development efforts. Combined high-throughput and multiplexing also deliver significant cost efficiency, reducing the cost per sample and expanding access to comprehensive epigenomic studies. “With EpiFinder™ cNUC, we aim to make epigenomics more accessible, scalable, and actionable for researchers working to understand complex diseases,” said Mohamad Takwa, CEO of Epigenica. “By enabling direct and multiplexed analysis of circulating nucleosomes, this product brings a new level of clarity to liquid biopsy research and supports the scientific community in accelerating discoveries that can ultimately benefit patients.” Engineered to support biomarker discovery and translational research across oncology, aging, inflammation, and other therapeutic areas, EpiFinder™ cNUC delivers the depth and resolution needed for drug development, early disease detection, patient stratification, disease‑progression monitoring, and treatment‑response evaluation. By enabling a multidimensional view of circulating nucleosome biology at scale, the product sets up a new standard for epigenomics in liquid biopsy. EpiFinder™ cNUC is available as a kit or as a fully supported service tailored to your needs. For product details or purchasing information, visit [www.epigenica.se](http://www.epigenica.se) or contact [sales@epigenica.se](mailto:sales@epigenica.se)  Categories: [Omics & Genetics](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics), [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) ##### Browse more news ## Recent releases #### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) July 6, 2026 Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) #### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) June 16, 2026 New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) #### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) June 16, 2026 Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)